NRx Pharmaceuticals (NRXP) Set to Release Earnings on Friday

NRx Pharmaceuticals (NASDAQ:NRXP) is anticipated to issue its Q3 2026 results on Friday, November 13th. Analysts expect NRx Pharmaceuticals to announce earnings of ($0.2125) per share and revenue of $1.28 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 16, 2026 at 8:30 AM ET.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.33). The firm had revenue of $1.10 million during the quarter, compared to the consensus estimate of $1.33 million. On average, analysts expect NRx Pharmaceuticals to post ($1.14) EPS for the current fiscal year and ($0.49) EPS for the next fiscal year.

NRx Pharmaceuticals Trading Up 3.4%

Shares of NASDAQ NRXP opened at $2.44 on Thursday. NRx Pharmaceuticals has a 12 month low of $1.62 and a 12 month high of $5.05. The stock has a 50 day moving average of $2.87 and a 200-day moving average of $2.96. The company has a market capitalization of $106.51 million, a P/E ratio of -4.44 and a beta of 2.11.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating on shares of NRx Pharmaceuticals in a research note on Tuesday, August 25th. Wall Street Zen lowered shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. UBS Group reiterated a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 26th. Wolfe Research assumed coverage on shares of NRx Pharmaceuticals in a report on Thursday, October 15th. They issued an “outperform” rating on the stock. Finally, Zacks Research cut shares of NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Wednesday, August 26th. Six research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.50.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly severe depression and suicidal ideation. The company’s research programs are designed to address conditions in which existing therapies may have limited effectiveness or delayed onset. NRx’s lead investigational product is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for bipolar depression with acute suicidal ideation.